López CSM, Jaime Carranza MJ

Language: Spanish
References: 22
Page: 378-384
PDF size: 649.31 Kb.

ABSTRACT

Background: Hypertension and metabolic syndrome compounds are the major non-transmissible chronic diseases in México. Its concomitance suggests a physiopathogenic link.
Objective: To determine the metabolic, vascular and mood features of hypertensive and non-hypertensive patients in México.
Material and Methods: Sequential, cross-sectional, open trial. One hundred and ninety patients were included and featured for hypertension, metabolic and vascular abnormalities, and mood disorders.
Results: There were 98 hypertensive patients, 95% had at least one of the metabolic syndrome compounds, and 74.2% had the whole metabolic syndrome. Obesity, hypertriglyceridemia, hypoalphalipoproteinemia, fasting disglycemia, insulin resistance, endothelial dysfunction and carotid atherosclerosis were more frequent in hypertensive patients.
Conclusions: All hypertensive patients in México must be considered metabolic subjects with all the diagnostic and therapeutic implications.

REFERENCES

1. Barquera S, Campos I, Hernández M, Rosas M, y col. Análisis de conglomerados de factores de riesgo para enfermedades crónicas en adultos mexicanos. Draft 2007.

2. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. JCEM 2001;86:5457-5464.

3. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25:1135-1141.

4. Correti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery. J Am Coll Cardiol 2002;39:257-265.

5. Neunteufl T, Heher S, Katzenchlager R, Wolf G. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000;86:207-210.

6. Al-Shali K, House AA, Hanley AJ, Khan HM, et al. Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis 2005;178:319-325.

7. Hegele RA, Al-Shali K, Khan HM, Hanley AJG, et al. Carotid ultrasound in one, two an three dimension. Vasc Dis Prevention 2005;2:87-92.

8. Bech P. Rating scales for mood disorders: Applicability, consistency and construct validity. Acta Psychiatr Scand 1988;78(Suppl 345):45-55.

9. Conde V, Useros E. Adaptación castellana de la escala de evaluación conductual para la depresión de Beck. Rev Psiquiatr Psicol Med Eur Am 1975;12:217-236.

10. Sharp LK, Lipsky MS. Screening for Depression Across the Lifespan: A Review of Measures for Use in Primary Care Settings. Am Fam Physician 2002;66:1001-1008.

11. Coleman A, Freeman P, Steel S, Shennan A. Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Pressure Monitoring 2006;11:27-32.

12. Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension

13. (ESH) and of the European Society of Cardiology (ESC). European Heart Journal Advance Access published June 11, 2007.

14. Tapia-Conyer R, Sarti E, Kuri P, Ruiz-Matus C, Velázquez O, y col. Metodología epidemiológica, en Roberto Tapia Conyer, editor. El Manual de Salud Pública. México: Intersistemas, 2006;1-57.

15. Barquera S, Campos-Nonato I, Hernández-Barrera L, Villalpando S, et al. Hypertension in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex 2010;52 suppl 1:S63-S71.

16. Insulin Resistance/Compensatory Hyperinsulinemia, Essential Hypertension, and Cardiovascular Disease. Reaven GM. Clin Endocrinol Metab 2003;88(6):2399-2403.

17. Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 1999;340(2):115-126.

18. Rosendo-Ballesteros N, Arceo-García MA, Carranza-Madrigal J. El tratamiento intensivo del síndrome metabólico reduce el nivel de riesgo cardiovascular. Med Int Mex 2010;26(5):421-430.

19. Pollex RL, Al-Shali KZ, House AA, et al. Relationship of the metabolic syndrome to carotid ultrasound traits. Cardiovascular Ultrasound 2006;4:28-46.

20. Weigensberg MJ, Toledo-Corral CM, Goran MI. Association between the Metabolic Syndrome and Serum Cortisol in Overweight Latino Youth. J Clin Endocrinol Metab 2008;93:1372-1378.

21. López SM, Alveano H, Carranza J. Prevalencia de síntomas depresivos en síndrome metabólico. Rev Fac Nac Salud Pública 2008;26(2):124-133.

22. Wang PS, Bohn RL, Knight E, Glynn RJ, et al. Noncompliance with antihypertensive medications. The impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002;17:504-511.